Results 11 to 20 of about 19,810 (255)

Peptide Receptor Radionuclide Therapy in Thyroid Cancer

Frontiers in Endocrinology, 2022
The treatment options that are currently available for management of metastatic, progressive radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary thyroid cancers (MTCs) are limited.
Sriram Gubbi, Christian A. Koch, Christian A. Koch, Joanna Klubo-Gwiezdzinska   +3 more
doaj   +3 more sources

Peptide receptor radionuclide therapy [PDF]

Best Practice & Research Clinical Gastroenterology, 2005
Peptide receptor radionuclide therapy is a new treatment modality for patients with inoperable or metastasised neuroendocrine gastroenteropancreatic tumours.
Esser, J.-P. (Jan-Paul), Jong, M. (Marcel) de, Krenning, E.P. (Eric), Kwekkeboom, D.J. (Dirk Jan), Teunissen, J.J.M. (Jaap), Valkema, R. (Roelf)   +5 more
core   +7 more sources

Thrombotic Microangiopathy From Peptide Receptor Radionuclide Therapy [PDF]

Kidney International Reports
In 2023, Schäfer et al.6 reported 3 cases of kidney failure after an overexposure to Lu-PSMA (8 to 10 cycles) because of renal-limited thrombotic microangiopathy (TMA). The outcome was poor because all of them had end-stage-kidney disease. However, the diagnostic work-up for TMA was limited (no genetic testing, no bone marrow examination, and no ...
Paul Delalande, Mickael Bobot, Marie Essig, Corinne Simon, Annie-Pierre Jonville-Béra, Christelle Barbet, Bénédicte Sautenet, Valentin Maisons, Thibaut Carsuzaa, Franck Bruyère, Jean-Michel Halimi   +10 more
doaj   +4 more sources

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor [PDF]

Case Reports in Oncology, 2020
Tumor-induced osteomalacia is a very rare paraneoplastic syndrome. It can be caused by phosphaturic mesenchymal tumor (PMT), a generally benign tumor that produces fibroblast growth factor 23 (FGF-23), which can cause a severe renal phosphate wasting ...
Simon Häfliger, Ann-Katrin Seidel, Eric Schoch, Jan Reichmann, Damian Wild, Stephanie Steinmann-Schwager, Miklos Pless   +6 more
doaj   +4 more sources

Peptide Receptor Radionuclide Therapy in the United States [PDF]

Journal of Nuclear Medicine, 2012
TO THE EDITOR: We read with great interest the article by Drs. Graham and Menda titled “Radiopeptide Imaging and Therapy in the United States” published in the recent supplement to The Journal of Nuclear Medicine ([1][1]).
Peeyush Bhargava, Ebrahim S. Delpassand
openalex   +3 more sources

Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms

Endocrine Oncology
Background: Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective.
Emma Boehm, Terry Hung, Tim Akhurst, Ramin Alipour, Cherie Chiang, Rodney J Hicks, Michael S Hofman, Aravind S Ravi Kumar, Nirupa Sachithanandan, Javad Saghebi, Michael Michael, Grace Kong   +11 more
doaj   +2 more sources

Peptide Receptor Radionuclide Therapy [PDF]

, 2020
Peptide receptor radionuclide therapy (PRRT) uses, as a therapeutic target, the overexpression of somatostatin receptors (SSTRs) in neuroendocrine tumours (NETs). The radiopharmaceutical contains generally a somatostatin analogue, which binds somatostatin receptors, and a linking molecule (chelator), which binds the radioisotope: most commonly Lutetium-
National Cancer Institute
  +4 more sources

Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors. [PDF]

Ann Surg Oncol
Borbon LC, Sherman SK, Breheny PJ, Chandrasekharan C, Menda Y, Bushnell D, Bellizzi AM, Ear PH, O'Dorisio MS, O'Dorisio TM, Dillon JS, Howe JR.   +11 more
europepmc   +3 more sources

Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series [PDF]

Archive of Oncology, 2012
Background: Peptide Receptor Radionuclide Therapy (PRRT) is novel and efficacious treatment of neuroendocrine tumors (NETs). Methods: Twenty-seven patients (14 females, 13 males, mean age 54.37±11.14 years; range 30-74 years) with progressive ...
Matović Milovan
doaj   +1 more source

Preclinical study of a new 177Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2020
Objective(s): Somatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years.
Hossein Behnammanesh, Mostafa Erfani, Maliheh Hajiramezanali, Safura Jokar, Parham Geramifar, Omid Sabzevari, Mohsen Amini, Mohammad Mazidi, Davood Beiki   +8 more
doaj   +1 more source